Karnidin

Lercanidipine Hydrochloride, the active ingredient in Karnidin, is a calcium channel blocker (dihydropyridine) presented as an oral dosage form for oral use. It treats hypertension in adult patients by lowering elevated blood pressure. GNH USA supplies Karnidin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lercanidipine Hydrochloride is a calcium channel blocker indicated for the management of hypertension. - Hypertension: reduces systolic and diastolic blood pressure to target levels. - Essential hypertension: provides long‑term control of primary high blood pressure. - High blood pressure: helps prevent cardiovascular complications associated with sustained elevation.

Lercanidipine may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate intensity, often transient. - Flushing: warm sensation with reddening of the skin. - Peripheral edema: swelling of the ankles or lower legs. - Dizziness: sensation of light‑headedness, especially after standing. - Tachycardia: increased heart rate without accompanying chest pain. - Palpitations: awareness of heartbeats.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips, tongue, or throat requiring emergency care. - Severe hypotension: marked drop in blood pressure leading to fainting. - Myocardial infarction: rare occurrence of heart attack. - Hepatic enzyme elevation: abnormal liver function tests. - Allergic reactions: rash, itching, or anaphylaxis. - Cardiac arrhythmias: irregular heart rhythms that may need monitoring.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential risks. - Blood pressure monitoring: check regularly to ensure therapeutic response and avoid overtreatment. - Hepatic impairment: use with caution in patients with liver dysfunction, adjusting dose if needed. - Concomitant antihypertensives: assess for additive blood‑pressure lowering effects. - Discontinuation: avoid abrupt cessation; taper if long‑term therapy is stopped. - Pregnancy and lactation: safety not established; prescribe only if benefit outweighs risk. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Lercanidipine can interact with several drug classes, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma concentrations and risk of hypotension. - Grapefruit juice: potentiates vasodilatory effect and can cause excessive blood‑pressure drop. - Simultaneous use with other dihydropyridine calcium channel blockers: may lead to additive cardiovascular effects.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce drug exposure, diminishing antihypertensive effect. - Diuretics: can enhance orthostatic hypotension; monitor volume status. - Beta‑blockers: may mask tachycardia; observe heart rate. - ACE inhibitors or ARBs: increased risk of renal impairment; check renal function. - NSAIDs: may attenuate antihypertensive response; assess blood pressure regularly.